

7-25-06 1617
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on July 24, 2006



SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1617
Patent Application
Docket No. MET-037CXT
Serial No. 09/900,364

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Leonard M. Williams
Art Unit : 1617
Applicants : Paul D. van Poelje, Mark D. Erion, Toshihiko Fujiwara
Serial No. : 09/900,364
Filed : July 5, 2001
Conf. No. : 7049
For : Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the
Treatment of Diabetes

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §§1.97 AND 1.98


Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicants have not submitted copies of the U.S. patents or published U.S. Patent Applications cited on attached Form PTO/SB/08 pursuant to 37 CFR 1.98(a)(2)(ii).

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/gyl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/900,364
				Filing Date	July 5, 2001
				First Named Inventor	Paul D. van Poelje
				Art Unit	1617
				Examiner Name	Leonard M. Williams
Sheet	1	of	1	Attorney Docket Number	MET-037CXT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-6,756,360	06-29-2004	Erion <i>et al.</i>	All
	U2	US-6,919,322	07-19-2005	Bookser <i>et al.</i>	All
	U3	US-6,965,033	11-15-2005	Jiang <i>et al.</i>	All
	U4	US-6,967,193	11-22-2005	Dang <i>et al.</i>	All
	U5	US-2004/0167178	08-26-2004	Erion <i>et al.</i>	All
	U6	US-2005/0004077	01-06-2005	Jiang <i>et al.</i>	All
	U7	US-2004/0058892	03-25-2004	Dang <i>et al.</i>	All
	U8	US-2005/0176684	08-11-2005	Bookser <i>et al.</i>	All
	U9				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 01/47935 CD-ROM	07-05-2001	Metabasis Therapeutics	All	
	F2	WO 01/66553 CD-ROM	09-13-2001	Metabasis Therapeutics	All	
	F3	WO 02/03978 CD-ROM	01-17-2002	Metabasis Therapeutics	All	
	F4	WO 06/023515 CD-ROM	03-02-2006	Metabasis Therapeutics	All	
	F5					

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.